Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hydroxyzine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 7/20 | 0.57 |
| ▸ | DRD3 | P35462 | 11/20 | 0.57 |
| ▸ | DRD2 | P14416 | 6/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | HTR2A | P28223 | 4/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.57 |
| ▸ | HTR6 | P50406 | 3/20 | 0.57 |
| ▸ | HRH2 | P25021 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 3/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.57 |
| ▸ | USP2 | O75604 | 3/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.57 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.57 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.57 |
| ▸ | DRD4 | P21917 | 1/20 | 0.57 |
| ▸ | HTR5A | P47898 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cetirizine SCHEMBL22832187 | 0.92 | DRD3 (0.59) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Etolotifen SCHEMBL2109044 | 0.83 | DRD3 (0.68) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Etolotifen SCHEMBL10851254 | 0.82 | DRD3 (0.67) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Oxatomide SCHEMBL2403337 | 0.77 | P2RX7 (0.60) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Hydroxyzine SCHEMBL4491 | 0.76 | DRD3 (1.00) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Hydroxyzine SCHEMBL383277 | 0.76 | DRD3 (1.00) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Hydroxyzine SCHEMBL3061159 | 0.76 | DRD3 (1.00) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Hydroxyzine SCHEMBL4492 | 0.76 | DRD3 (1.00) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Hydroxyzine SCHEMBL491323 | 0.75 | DRD3 (0.98) | DRD3HRH1DRD2CHRM2ADRA2A | |
| Hydroxyzine SCHEMBL41448 | 0.75 | DRD3 (0.98) | DRD3HRH1DRD2CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101355876-B | Composition suitable for ophthalmic administration | COMBINATORX INC | 2012-09-05 | — | — | CN | disclosed |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | disclosed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | disclosed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| WO-2010048264-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-04-29 | — | — | WO | disclosed |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | CombinatoRx, (Singapore) Pte. Ltd. | 2010-04-01 | — | — | US | disclosed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-1670427-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| EP-1680121-A4 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1599212-A4 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX INC (US) | 2006-02-08 | — | — | EP | disclosed |
| EP-1599212-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | Combinatorx, Incorporated (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INCORPORATED | 2005-09-01 | — | — | US | disclosed |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. | 2005-06-02 | — | — | US | disclosed |
| US-20050112199-A1 | Therapeutic regimens for administering drug combinations | COMBINATORX, INCORPORATED | 2005-05-26 | — | — | US | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005030132-A2 | THERAPEUTIC REGIMENS FOR ADMINISTERING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005027839-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | COMBINATORX, INCORPORATED | 2004-11-11 | — | — | US | disclosed |
| WO-2004073614-A2 | COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192261-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, CMA1, CCL11 | HRH1 13/4885DRD3 2148/4885DRD2 2151/4885 |
| US-20040224876-A1 | Combination therapy for the treatment of immunoinflammatory disorders | HLA-DRB1, TSLP, SERPINA6 | HRH1 1423/4885DRD3 2199/4885DRD2 3053/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | HRH1 2332/4885DRD3 3148/4885DRD2 3169/4885 |
| US-20100081713-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | IFNG, IL5, HAVCR2 | HRH1 1434/4885DRD3 4773/4885DRD2 4839/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | HRH1 1027/4885DRD3 4591/4885DRD2 4506/4885 |
| US-20050119160-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | HRH1 1027/4885DRD3 4591/4885DRD2 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.